1. Lambent LM, Bourgeois AL, Fischer-Walker CL, Black RE, Sack D (2014) Estimating diarrheal illness and deaths attributable to Shigellae and enterotoxigenic Escherichia coli among older children, adolescents, and adults in South Asia and Africa. PLoS Negl Trop Dis 8(2):e2705
2. Guidelines for the control of epidemics due to Shigella dysenteriae type 1. WHO/CDR/95.4.2006. Recommendations to assure the quality, safety and efficacy of group A Meningococcal conjugate vaccines. WHO/BS/06.2041.
3. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM (1999) Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. WHO 77(8):651–666
4. Changfa C, Carbis R, Jung S, An SJ, Jang H, Czerkinsky C, Szu S, Clemens JD (2010) Physical and chemical characterization and immunologic properties of salmonella enteric serovar Typhi capsular polysaccharide-diphtheria toxoid conjugates. Am Soc Microbiol 17(1):73–79
5. Hu Q-Y, Allan M, Adamo R, Quinn D, Zhai H, Wu G, Clark K, Zhou J, Ortiz S, Wang B, Danieli E, Crotti S, Tontini M, Brogioni G, Berti F (2013) Synthesis of a well-defined glycoconjugate vaccine by a tyrosine-selective conjugation strategy. Chem Sci 4:3827–3832